Overview

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

Status:
Completed
Trial end date:
2021-08-11
Target enrollment:
Participant gender:
Summary
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals